ArticleMedeniyet medical journal2026
Investigation of Serum Claudin-5 Levels in Patients with Heroin Addiction.
Article in Medeniyet medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In this study, we investigated the potential effects of heroin on the blood-brain barrier (BBB) through the claudin-5 protein. Methods: A total of 108 subjects participated in this study, of whom 53 were individuals with heroin addiction (HA) and 55 were healthy controls (C). 26 patients were active heroin users (AHU), and 27 were in remission (R). Results: Our results show that claudin-5 levels were significantly elevated in the HA group compared with healthy individuals. This elevation was present in both HA subgroups (AHU and R). In our receiver operating characteristic analysis to determine the discriminatory power of claudin-5 values, we obtained the highest area under the curve (AUC) values for the comparison of the R-C group, the HA-C group, and the AHU-C group (AUC: 0.824, 0.813, 0.803, respectively). Conclusions: Our results suggest that serum claudin-5 concentrations are significantly elevated in individuals with HA, regardless of the current phase of drug use, indicating persistent changes in the BBB. Claudin-5 may be a promising peripheral biomarker for heroin-related neurovascular disorder. However, further longitudinal and mechanistic studies are needed to elucidate the temporal dynamics of claudin-5 expression and its relationship to neurobiological recovery during R.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.